Skip to main content
Midas Edge

HCW Biologics Inc.

For the period ended Dec 31, 2025. Filed Mar 31, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 31, 2026

HCWB$0.95-6.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Balance Sheets

December 31,December 31,
20242025
ASSETS
Current assets:
Cash and cash equivalents$4,674,572$1,952,464
Accounts receivable, net582,20132,175
Prepaid expenses328,181222,156
Other current assets113,52877,564
Total current assets5,698,4822,284,359
Investments1,599,7511,326,329
Property, plant and equipment, net22,909,86920,880,849
Other assets28,47628,476
Total assets$30,236,578$24,520,013
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Liabilities
Current liabilities:
Accounts payable$22,332,261$13,143,394
Accrued liabilities and other current liabilities981,9401,110,104
Short-term debt, net6,314,6846,809,215
Total current liabilities29,628,88521,062,713
Debt, net7,377,865—
Contingent liability - related party—692,531
Total liabilities37,006,75021,755,244
Commitments and contingencies (Note 17)
Stockholders’ equity (deficit):
Common stock:
Common, $0.0001 par value; 250,000,000 shares authorized and 1,113,532 shares issued at December 31, 2024; 250,000,000 shares authorized and 3,279,812 shares issued at December 31, 2025111328
Additional paid-in capital93,785,854111,280,287
Accumulated deficit(100,556,137)(108,515,846)
Total stockholders’ equity (deficit)(6,770,172)2,764,769
Total liabilities and stockholders’ equity (deficit)$30,236,578$24,520,013
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.